{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:43:47Z","timestamp":1780818227540,"version":"3.54.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>There is ongoing debate concerning the classification of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. That is, whether classification should be based on the serotype (proteinase 3 (PR3)- or myeloperoxidase (MPO)-ANCA) or on the clinical phenotype (granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)). To add clarity, this review focused on integration of the most recent literature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Large clinical trials have provided evidence that a serology-based risk assessment for relapses is more predictive than distinction based on the phenotype. Research conducted in the past decade indicated that a serology-based approach more closely resembles the genetic associations, the clinical presentation (i.e., lung involvement), biomarker biology, treatment response, and is also predicting comorbidities (such as cardiovascular death).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Our review highlights that a serology-based approach could replace a phenotype-based approach to classify ANCA-associated vasculitides. In future, clinical trials and observational studies will presumably focus on this distinction and, as such, translate into a \u201cpersonalized medicine.\u201d<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11926-021-01002-0","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T15:59:09Z","timestamp":1619625549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["ANCA Status or Clinical Phenotype \u2014 What Counts More?"],"prefix":"10.1007","volume":"23","author":[{"given":"Martin","family":"Windpessl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Bettac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Gauckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Il","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-2946","authenticated-orcid":false,"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"issue":"8426","key":"1002_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0140-6736(85)91147-X","volume":"1","author":"FJ van der Woude","year":"1985","unstructured":"van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener\u2019s granulomatosis. Lancet. 1985;1(8426):425\u20139.","journal-title":"Lancet."},{"issue":"3","key":"1002_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1681\/ASN.2013111233","volume":"26","author":"MJ Kemna","year":"2015","unstructured":"Kemna MJ, Damoiseaux J, Austen J, Winkens B, Peters J, van Paassen P, et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol. 2015;26(3):537\u201342.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"1002_CR3","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1002\/art.39786","volume":"68","author":"JH Schirmer","year":"2016","unstructured":"Schirmer JH, Wright MN, Herrmann K, Laudien M, N\u00f6lle B, Reinhold-Keller E, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener\u2019s) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German vasculitis referral center. Arthritis Rheumatol. 2016;68(12):2953\u201363.","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"1002_CR4","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1111\/j.1523-1755.2005.00679.x","volume":"68","author":"M Chen","year":"2005","unstructured":"Chen M, Yu F, Zhang Y, Zou WZ, Zhao MH, Wang HY. Characteristics of Chinese patients with Wegener\u2019s granulomatosis with anti-myeloperoxidase autoantibodies. Kidney Int. 2005;68(5):2225\u20139.","journal-title":"Kidney Int"},{"issue":"7","key":"1002_CR5","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"\u2022\u2022 Walsh M, Merkel PA, Peh CA, Szpirt WM, Pu\u00e9chal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622\u201331. Plasma exchange did not decrease the composite of end-stage kidney disease or death in severe ANCA-associated vasculitis, but a reduced-dose regimen of glucocorticoids was non-inferior compared to the standard-dosed regimen, with a reduced occurrence of severe infections at 1 year.","journal-title":"N Engl J Med"},{"issue":"3","key":"1002_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221\u201332.","journal-title":"N Engl J Med"},{"issue":"3","key":"1002_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211\u201320.","journal-title":"N Engl J Med"},{"issue":"1","key":"1002_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1\u201311.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1002_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","volume":"26","author":"M Groh","year":"2015","unstructured":"Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545\u201353.","journal-title":"Eur J Intern Med"},{"issue":"11","key":"1002_CR10","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00296-019-04447-w","volume":"39","author":"SM Kim","year":"2019","unstructured":"Kim SM, Choi SY, Kim SY, Kim J. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study. Rheumatol Int. 2019;39(11):1919\u201326.","journal-title":"Rheumatol Int"},{"issue":"2","key":"1002_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.ajkd.2005.05.003","volume":"46","author":"A Rutgers","year":"2005","unstructured":"Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert JW. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis. 2005;46(2):253\u201362.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1002_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","volume":"92","author":"SP McAdoo","year":"2017","unstructured":"\u2022 McAdoo SP, Tanna A, Hru\u0161kov\u00e1 Z, Holm L, Weiner M, Arulkumaran N, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92(3):693\u2013702. Description of double-positive patients (ANCA-associated vasculitis + anti-GBM disease) as a hybrid disease, with features of both diseases (older age distribution, diagnostic delay, severe kidney disease, and lung hemorrhage at presentation).","journal-title":"Kidney Int"},{"issue":"6","key":"1002_CR13","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1046\/j.1523-1755.2000.00080.x","volume":"57","author":"CF Franssen","year":"2000","unstructured":"Franssen CF, Stegeman CA, Kallenberg CG, Gans RO, De Jong PE, Hoorntje SJ, et al. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int. 2000;57(6):2195\u2013206.","journal-title":"Kidney Int"},{"key":"1002_CR14","doi-asserted-by":"publisher","unstructured":"\u2022 Delaval L, Samson M, Schein F, Agard C, Tr\u00e9fond L, Deroux A, et al. Temporal arteritis revealing antineutrophil cytoplasmic antibody-associated vasculitides: case-control study of 50 cases. Arthritis Rheumatol. 2021;73(2):286\u201394. https:\/\/doi.org\/10.1002\/art.41527. Cases with temporal arteritis and underlying ANCA-associated vasculitis are described retrospectively, with a median diagnostic delay of 15 months in 60% of patients.","DOI":"10.1002\/art.41527"},{"issue":"7","key":"1002_CR15","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/art.39614","volume":"68","author":"RL Rhee","year":"2016","unstructured":"Rhee RL, Hogan SL, Poulton CJ, McGregor JA, Landis JR, Falk RJ, et al. Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease. Arthritis Rheumatol. 2016;68(7):1711\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"1002_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3389\/fimmu.2020.00525","volume":"11","author":"L Shochet","year":"2020","unstructured":"Shochet L, Holdsworth S, Kitching AR. Animal models of ANCA associated vasculitis. Front Immunol. 2020;11:525.","journal-title":"Front Immunol"},{"issue":"7","key":"1002_CR17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.amjmed.2006.08.016","volume":"120","author":"JD Finkielman","year":"2007","unstructured":"Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, et al. ANCA are detectable in nearly all patients with active severe Wegener\u2019s granulomatosis. Am J Med. 2007;120(7):643\u2013e9-14.","journal-title":"Am J Med"},{"issue":"10","key":"1002_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","volume":"12","author":"D Cornec","year":"2016","unstructured":"Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis\u2014clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016;12(10):570\u20139.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"1002_CR19","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1097\/RHU.0000000000000813","volume":"25","author":"CH Mu\u00f1oz-Vahos","year":"2019","unstructured":"Mu\u00f1oz-Vahos CH, Herrera-Uribe S, Arbel\u00e1ez-Cort\u00e9s \u00c1, Jaramillo-Arroyave D, Gonz\u00e1lez-Naranjo LA, V\u00e1squez-Duque G, et al. Clinical profile of levamisole-adulterated cocaine-induced vasculitis\/vasculopathy: a 30-case series. J Clin Rheumatol. 2019;25(3):e16\u201326.","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"1002_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/1529-0131(200002)43:2<405::AID-ANR22>3.0.CO;2-5","volume":"43","author":"HK Choi","year":"2000","unstructured":"Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum. 2000;43(2):405\u201313.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1002_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/art.20927","volume":"53","author":"MC Slot","year":"2005","unstructured":"Slot MC, Links TP, Stegeman CA, Tervaert JW. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a long-term followup study. Arthritis Rheum. 2005;53(1):108\u201313.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1002_CR22","doi-asserted-by":"publisher","first-page":"102618","DOI":"10.1016\/j.autrev.2020.102618","volume":"19","author":"S Moiseev","year":"2020","unstructured":"Moiseev S, Cohen Tervaert JW, Arimura Y, Bogdanos DP, Csernok E, Damoiseaux J, et al. 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev. 2020;19(9):102618.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"1002_CR23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/RHU.0b013e31826d2005","volume":"18","author":"SP McAdoo","year":"2012","unstructured":"McAdoo SP, Hall A, Levy J, Salama AD, Pusey CD. Proteinase-3 antineutrophil cytoplasm antibody positivity in patients without primary systemic vasculitis. J Clin Rheumatol. 2012;18(7):336\u201340.","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"1002_CR24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/annrheumdis-2016-209507","volume":"76","author":"J Damoiseaux","year":"2017","unstructured":"Damoiseaux J, Csernok E, Rasmussen N, Moosig F, van Paassen P, Baslund B, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis. 2017;76(4):647\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1002_CR25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","volume":"13","author":"X Bossuyt","year":"2017","unstructured":"Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Su\u00e1rez LF, Guillevin L, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017;13(11):683\u201392.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1002_CR26","doi-asserted-by":"publisher","first-page":"102716","DOI":"10.1016\/j.autrev.2020.102716","volume":"20","author":"NAD Guchelaar","year":"2021","unstructured":"Guchelaar NAD, Waling MM, Adhin AA, van Daele PLA, Schreurs MWJ, Rombach SM. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis. Autoimmun Rev. 2021;20(1):102716.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1002_CR27","doi-asserted-by":"publisher","first-page":"e12958","DOI":"10.1111\/sji.12958","volume":"92","author":"RK Sharma","year":"2020","unstructured":"Sharma RK, L\u00f6vstr\u00f6m B, Gunnarsson I, Malmstr\u00f6m V. Proteinase 3 autoreactivity in anti-neutrophil cytoplasmic antibody-associated vasculitis-immunological versus clinical features. Scand J Immunol. 2020;92(5):e12958.","journal-title":"Scand J Immunol"},{"issue":"3","key":"1002_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa1108735","volume":"367","author":"PA Lyons","year":"2012","unstructured":"Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214\u201323.","journal-title":"N Engl J Med"},{"issue":"11","key":"1002_CR29","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1002\/art.41011","volume":"71","author":"EY Wu","year":"2019","unstructured":"\u2022\u2022 Wu EY, McInnis EA, Boyer-Suavet S, Mendoza CE, Aybar LT, Kennedy KB, et al. Measuring circulating complement activation products in myeloperoxidase- and proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2019;71(11):1894\u2013903. Circulating complement activation products were measured in 98 patients, with higher levels of C3a, C5a, and sC5b-9 in active cases compared to controls. Some complement products remained elevated during remission phase.","journal-title":"Arthritis Rheumatol"},{"key":"1002_CR30","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cei.13498","volume":"202","author":"S Moiseev","year":"2020","unstructured":"Moiseev S, Lee JM, Zykova A, Bulanov N, Novikov P, Gitel E, et al. The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis. Clin Exp Immunol. 2020;202:394\u2013402.","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"1002_CR31","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3899\/jrheum.131038","volume":"41","author":"AJ Mohammad","year":"2014","unstructured":"Mohammad AJ, Segelmark M. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol. 2014;41(7):1366\u201373.","journal-title":"J Rheumatol"},{"issue":"7","key":"1002_CR32","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/art.40471","volume":"70","author":"A Berti","year":"2018","unstructured":"\u2022\u2022 Berti A, Warner R, Johnson K, Cornec D, Schroeder D, Kabat B, et al. Brief report: circulating cytokine profiles and antineutrophil cytoplasmic antibody specificity in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2018;70(7):1114\u201321. A panel of 29 cytokines was tested in 186 patients recruited to the RAVE trial. Analysis found that the difference of cytokine expression was in most cases larger between PR3-ANCA vasculitis and MPO-ANCA vasculitis as compared to a phenotype (GPA and MPA)-based distinction.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"1002_CR33","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/ndt\/gfu084","volume":"29","author":"LF Quintana","year":"2014","unstructured":"Quintana LF, Per\u00e9z NS, De Sousa E, Rodas LM, Griffiths MH, Sol\u00e9 M, et al. ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 2014;29(9):1764\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1002_CR34","first-page":"301","volume":"34","author":"M Weiner","year":"2019","unstructured":"Weiner M, Bj\u00f8rneklett R, Hru\u0161kov\u00e1 Z, Mackinnon B, Poulton CJ, Sindelar L, et al. Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrol Dial Transplant. 2019;34(2):301\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"1002_CR35","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1002\/art.34562","volume":"64","author":"S Lionaki","year":"2012","unstructured":"Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452\u201362.","journal-title":"Arthritis Rheum"},{"key":"1002_CR36","doi-asserted-by":"publisher","unstructured":"Micheletti RG, Chiesa Fuxench Z, Craven A, Watts RA, Luqmani RA, Merkel PA, et al. Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2020;72(10):1741\u20137. https:\/\/doi.org\/10.1002\/art.41310.","DOI":"10.1002\/art.41310"},{"issue":"4","key":"1002_CR37","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","volume":"41","author":"AD Booth","year":"2003","unstructured":"Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41(4):776\u201384.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"1002_CR38","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1681\/ASN.V9101915","volume":"9","author":"CF Franssen","year":"1998","unstructured":"Franssen CF, Stegeman CA, Oost-Kort WW, Kallenberg CG, Limburg PC, Tiebosch A, et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. J Am Soc Nephrol. 1998;9(10):1915\u201323.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"1002_CR39","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/ndt\/gfy250","volume":"34","author":"A Berti","year":"2019","unstructured":"Berti A, Cornec-Le Gall E, Cornec D, Casal Moura M, Matteson EL, Crowson CS, et al. Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrol Dial Transplant. 2019;34(9):1508\u201317.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1002_CR40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1002_CR41","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1046\/j.1523-1755.2002.00605.x","volume":"62","author":"HA Hauer","year":"2002","unstructured":"Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, No\u00ebl LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002;62(5):1732\u201342.","journal-title":"Kidney Int"},{"issue":"3","key":"1002_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/ajkd.2003.50142","volume":"41","author":"A Vizjak","year":"2003","unstructured":"Vizjak A, Rott T, Koselj-Kajtna M, Rozman B, Kaplan-Pavlovcic S, Ferluga D. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. Am J Kidney Dis. 2003;41(3):539\u201349.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"1002_CR43","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2010050477","volume":"21","author":"AE Berden","year":"2010","unstructured":"Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628\u201336.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1002_CR44","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1159\/000494840","volume":"48","author":"S Menez","year":"2018","unstructured":"Menez S, Hruskova Z, Scott J, Cormican S, Chen M, Salama AD, et al. Predictors of renal outcomes in sclerotic class anti-neutrophil cytoplasmic antibody glomerulonephritis. Am J Nephrol. 2018;48(6):465\u201371.","journal-title":"Am J Nephrol"},{"key":"1002_CR45","doi-asserted-by":"publisher","unstructured":"\u2022 van Daalen EE, Wester Trejo MAC, G\u00f6\u00e7ero\u011flu A, Ferrario F, Joh K, No\u00ebl LH, et al. Developments in the histopathological classification of ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol. 2020;15(8):1103\u201311. https:\/\/doi.org\/10.2215\/CJN.14561119. Long-term kidney survival (8 years of follow-up) is different among the four histopathological classes (focal, crescentic, mixed, and sclerotic). Application of the ANCA kidney risk score indicated that those belonging to the low or medium risk groups have excellent 3-year kidney survival (100 and 96%).","DOI":"10.2215\/CJN.14561119"},{"issue":"3","key":"1002_CR46","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3899\/jrheum.160866","volume":"44","author":"YX Chen","year":"2017","unstructured":"Chen YX, Xu J, Pan XX, Shen PY, Li X, Ren H, et al. Histopathological classification and renal outcome in patients with antineutrophil cytoplasmic antibodies-associated renal vasculitis: a study of 186 patients and metaanalysis. J Rheumatol. 2017;44(3):304\u201313.","journal-title":"J Rheumatol"},{"issue":"7","key":"1002_CR47","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/ndt\/gfu237","volume":"30","author":"A Tanna","year":"2015","unstructured":"Tanna A, Guarino L, Tam FW, Rodriquez-Cubillo B, Levy JB, Cairns TD, et al. Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrol Dial Transplant. 2015;30(7):1185\u201392.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"1002_CR48","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.kint.2018.07.020","volume":"94","author":"SR Brix","year":"2018","unstructured":"Brix SR, Noriega M, Tennstedt P, Vettorazzi E, Busch M, Nitschke M, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94(6):1177\u201388.","journal-title":"Kidney Int"},{"issue":"3","key":"1002_CR49","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ekir.2018.01.012","volume":"3","author":"TK Novick","year":"2018","unstructured":"Novick TK, Chen M, Scott J, Cortazar FB, Ayoub I, Little MA, et al. Patient outcomes in renal-limited antineutrophil cytoplasmic antibody vasculitis with inactive histology. Kidney Int Rep. 2018;3(3):671\u20136.","journal-title":"Kidney Int Rep"},{"issue":"suppl_1","key":"1002_CR50","doi-asserted-by":"publisher","first-page":"i139","DOI":"10.1093\/ndt\/gfw299","volume":"32","author":"S Sethi","year":"2017","unstructured":"Sethi S, Zand L, De Vriese AS, Specks U, Vrana JA, Kanwar S, et al. Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrol Dial Transplant. 2017;32(suppl_1):i139\u2013i45.","journal-title":"Nephrol Dial Transplant"},{"key":"1002_CR51","doi-asserted-by":"publisher","unstructured":"Trivioli G, Gopaluni S, Urban ML, Gianfreda D, Cassia MA, Vercelloni PG, et al. Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome. Clin Kidney J. 2020;14(1):332\u201340. https:\/\/doi.org\/10.1093\/ckj\/sfaa139.","DOI":"10.1093\/ckj\/sfaa139"},{"issue":"4","key":"1002_CR52","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.kint.2019.04.045","volume":"96","author":"JR Smith","year":"2019","unstructured":"Smith JR, Methven S, Stevens KI, MacKinnon B, Kidder D. Renal risk score performance in a cohort of Scottish patients with ANCA-associated glomerulonephritis. Kidney Int. 2019;96(4):1037.","journal-title":"Kidney Int"},{"issue":"9","key":"1002_CR53","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/ndt\/gfx248","volume":"32","author":"D Jayne","year":"2017","unstructured":"Jayne D. Vasculitis-when can biopsy be avoided? Nephrol Dial Transplant. 2017;32(9):1454\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"1002_CR54","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/art.39562","volume":"68","author":"R Cartin-Ceba","year":"2016","unstructured":"Cartin-Ceba R, Diaz-Caballero L, Al-Qadi MO, Tryfon S, Fervenza FC, Ytterberg SR, et al. Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes. Arthritis Rheumatol. 2016;68(6):1467\u201376.","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"1002_CR55","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3899\/jrheum.161224","volume":"44","author":"AJ Mohammad","year":"2017","unstructured":"\u2022 Mohammad AJ, Mortensen KH, Babar J, Smith R, Jones RB, Nakagomi D, et al. Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: the influence of ANCA subtype. J Rheumatol. 2017;44(10):1458\u201367. This study investigated pulmonary involvement in 140 patients with ANCA-associated vasculitis and found different patterns of abnormalities exclusively in patients with PR3-ANCA and MPO-ANCA vasculitis.","journal-title":"J Rheumatol"},{"issue":"6","key":"1002_CR56","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0025-6196(12)62575-0","volume":"65","author":"AK Nada","year":"1990","unstructured":"Nada AK, Torres VE, Ryu JH, Lie JT, Holley KE. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc. 1990;65(6):847\u201356.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1002_CR57","first-page":"46","volume":"35","author":"Y Arimura","year":"1995","unstructured":"Arimura Y, Minoshima S, Tanaka U, Fujii A, Kobayashi M, Nakabayashi K, et al. Pulmonary involvement in patients with myeloperoxidase specific-antineutrophil cytoplasmic antibody. Ryumachi. 1995;35(1):46\u201355.","journal-title":"Ryumachi."},{"issue":"4","key":"1002_CR58","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000183754","volume":"77","author":"T Nozu","year":"2009","unstructured":"Nozu T, Kondo M, Suzuki K, Tamaoki J, Nagai A. A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients. Respiration. 2009;77(4):407\u201315.","journal-title":"Respiration."},{"issue":"24","key":"1002_CR59","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/MD.0000000000000217","volume":"93","author":"C Comarmond","year":"2014","unstructured":"Comarmond C, Crestani B, Tazi A, Hervier B, Adam-Marchand S, Nunes H, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore). 2014;93(24):340\u20139.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1002_CR60","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/rheumatology\/kev286","volume":"55","author":"JH Schirmer","year":"2016","unstructured":"Schirmer JH, Wright MN, Vonthein R, Herrmann K, N\u00f6lle B, Both M, et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford). 2016;55(1):71\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1002_CR61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1378\/chest.123.1.297","volume":"123","author":"GM Eschun","year":"2003","unstructured":"Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest. 2003;123(1):297\u2013301.","journal-title":"Chest."},{"issue":"4","key":"1002_CR62","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.rmed.2013.01.006","volume":"107","author":"M Ando","year":"2013","unstructured":"Ando M, Miyazaki E, Ishii T, Mukai Y, Yamasue M, Fujisaki H, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med. 2013;107(4):608\u201315.","journal-title":"Respir Med"},{"issue":"7","key":"1002_CR63","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.autrev.2017.05.008","volume":"16","author":"MA Alba","year":"2017","unstructured":"Alba MA, Flores-Su\u00e1rez LF, Henderson AG, Xiao H, Hu P, Nachman PH, et al. Interstital lung disease in ANCA vasculitis. Autoimmun Rev. 2017;16(7):722\u20139.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1002_CR64","first-page":"221","volume":"38 Suppl 124","author":"M Sebastiani","year":"2020","unstructured":"Sebastiani M, Manfredi A, Vacchi C, Cassone G, Faverio P, Cavazza A, et al. Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis. Clin Exp Rheumatol. 2020;38 Suppl 124(2):221\u201331.","journal-title":"Clin Exp Rheumatol"},{"key":"1002_CR65","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 McDermott G, Fu X, Stone JH, Wallwork R, Zhang Y, Choi HK, et al. Association of cigarette smoking with antineutrophil cytoplasmic antibody-associated vasculitis. JAMA Intern Med. 2020;180(6):870\u20136. A dose-response relationship of cigarette smoking and ANCA-associated vasculitis risk was reported. This association was particularly strong among patients with MPO-ANCA vasculitis (former and current smokers).","DOI":"10.1001\/jamainternmed.2020.0675"},{"issue":"26","key":"1002_CR66","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"1002_CR67","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1055\/s-0038-1673386","volume":"39","author":"MA Alba","year":"2018","unstructured":"Alba MA, Jennette JC, Falk RJ. Pathogenesis of ANCA-associated pulmonary vasculitis. Semin Respir Crit Care Med. 2018;39(4):413\u201324.","journal-title":"Semin Respir Crit Care Med"},{"issue":"6","key":"1002_CR68","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2012-201750","volume":"72","author":"A Mahr","year":"2013","unstructured":"Mahr A, Katsahian S, Varet H, Guillevin L, Hagen EC, H\u00f6glund P, et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis. 2013;72(6):1003\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1002_CR69","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","volume":"75","author":"S Unizony","year":"2016","unstructured":"Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75(6):1166\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1002_CR70","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ekir.2018.05.007","volume":"3","author":"D Geetha","year":"2018","unstructured":"Geetha D, Jin Q, Scott J, Hruskova Z, Hanouneh M, Little MA, et al. Comparisons of guidelines and recommendations on managing antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep. 2018;3(5):1039\u201349.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"1002_CR71","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/M19-3827","volume":"173","author":"P Charles","year":"2020","unstructured":"\u2022 Charles P, Perrodeau \u00c9, Samson M, Bonnotte B, N\u00e9el A, Agard C, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2020;173(3):179\u201387. This randomized controlled trial found that patients who are in remission after 28 months benefit from additional rituximab infusions (relapse-free survival at 28 months of 96% compared to 74% in the placebo arm). In the placebo group, relapse was more common in PR3-ANCA vasculitis (10\/25 patients versus 2\/17 patients with MPO-ANCA vasculitis).","journal-title":"Ann Intern Med"},{"issue":"3","key":"1002_CR72","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","volume":"78","author":"RB Jones","year":"2019","unstructured":"Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019;78(3):399\u2013405.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1002_CR73","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"\u2022\u2022 Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756\u201367. In this phase 2 trial, the addition of avacopan to an induction regimen of rituximab or cyclophosphamide + low-dose prednisone or without prednisone was non-inferior to a standard of care treatment regimen. Adverse events were similar among the three groups of patients.","journal-title":"J Am Soc Nephrol"},{"issue":"Supplement_3","key":"1002_CR74","doi-asserted-by":"publisher","first-page":"iii79","DOI":"10.1093\/rheumatology\/kez617","volume":"59","author":"A Kronbichler","year":"2020","unstructured":"Kronbichler A, Leierer J, Gauckler P, Shin JI. Comorbidities in ANCA-associated vasculitis. Rheumatology (Oxford). 2020;59(Supplement_3):iii79\u201383.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1002_CR75","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1002\/art.24957","volume":"60","author":"MD Morgan","year":"2009","unstructured":"Morgan MD, Turnbull J, Selamet U, Kaur-Hayer M, Nightingale P, Ferro CJ, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum. 2009;60(11):3493\u2013500.","journal-title":"Arthritis Rheum"},{"key":"1002_CR76","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Wallace ZS, Fu X, Harkness T, Stone JH, Zhang Y, Choi H. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. Rheumatology (Oxford). 2020;59(9):2308\u201315. https:\/\/doi.org\/10.1093\/rheumatology\/kez589. This retrospective cohort study found that in comparison to patients with PR3-ANCA vasculitis, MPO-ANCA positive patients had a higher risk of cardiovascular disease-related death, even after adjustment for confounders.","DOI":"10.1093\/rheumatology\/kez589"},{"issue":"11","key":"1002_CR77","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/art.41006","volume":"71","author":"ZS Wallace","year":"2019","unstructured":"Wallace ZS, Fu X, Liao K, Kallenberg CGM, Langford CA, Merkel PA, et al. Disease activity, antineutrophil cytoplasmic antibody type, and lipid levels in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2019;71(11):1879\u201387.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1002_CR78","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/jep.12709","volume":"23","author":"CP Bramlage","year":"2017","unstructured":"Bramlage CP, Kr\u00f6plin J, Wallbach M, Minguet J, Smith KH, L\u00fcders S, et al. Management of cardiovascular risk factors in patients with ANCA-associated vasculitis. J Eval Clin Pract. 2017;23(4):747\u201354.","journal-title":"J Eval Clin Pract"},{"issue":"8","key":"1002_CR79","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-142-8-200505030-00011","volume":"142","author":"PA Merkel","year":"2005","unstructured":"Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis JC, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener\u2019s Clinical Occurrence of Thrombosis (WeCLOT) study. Ann Intern Med. 2005;142(8):620\u20136.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1002_CR80","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/ard.2008.099051","volume":"68","author":"Y Allenbach","year":"2009","unstructured":"Allenbach Y, Seror R, Pagnoux C, Teixeira L, Guilpain P, Guillevin L, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener\u2019s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009;68(4):564\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1002_CR81","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/rheumatology\/ken035","volume":"47","author":"PM Stassen","year":"2008","unstructured":"Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis\u2014incidence and risk factors. Rheumatology (Oxford). 2008;47(4):530\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1002_CR82","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1136\/annrheumdis-2014-206849","volume":"74","author":"P Novikov","year":"2015","unstructured":"Novikov P, Makarov E, Moiseev S, Meshkov A, Strizhakov L. Venous thromboembolic events in systemic vasculitis. Ann Rheum Dis. 2015;74(3):e27.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1002_CR83","first-page":"704","volume":"56","author":"A Kronbichler","year":"2017","unstructured":"Kronbichler A, Leierer J, Leierer G, Mayer G, Casian A, H\u00f6glund P, et al. Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides. Rheumatology (Oxford). 2017;56(5):704\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1002_CR84","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3899\/jrheum.170896","volume":"46","author":"A Kang","year":"2019","unstructured":"Kang A, Antonelou M, Wong NL, Tanna A, Arulkumaran N, Tam FWK, et al. High incidence of arterial and venous thrombosis in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2019;46(3):285\u201393.","journal-title":"J Rheumatol"},{"issue":"5","key":"1002_CR85","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.mayocp.2018.02.010","volume":"93","author":"A Berti","year":"2018","unstructured":"Berti A, Matteson EL, Crowson CS, Specks U, Cornec D. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: a 20-year population-based cohort study. Mayo Clin Proc. 2018;93(5):597\u2013606.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"1002_CR86","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/art.41017","volume":"71","author":"A Kronbichler","year":"2019","unstructured":"\u2022 Kronbichler A, Leierer J, Shin JI, Merkel PA, Spiera R, Seo P, et al. Association of pulmonary hemorrhage, positive proteinase 3, and urinary red blood cell casts with venous thromboembolism in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2019;71(11):1888\u201393. In this sub-analysis of the RAVE trial, PR3-ANCA positivity, pulmonary hemorrhage, and the presence of red blood cell casts in the urine associated with an increased risk of venous thromboembolic events in patients with ANCA-associated vasculitis.","journal-title":"Arthritis Rheumatol"},{"key":"1002_CR87","doi-asserted-by":"crossref","unstructured":"Henry N, Brilland B, Wacrenier S, Djema A, Garnier AS, Gansey R, et al. Incidence and risk factors of venous thromboembolic events in patients with ANCA-glomerulonephritis: a cohort study from the Maine-Anjou Registry. J Clin Med. 2020;9(10).","DOI":"10.3390\/jcm9103177"},{"issue":"12","key":"1002_CR88","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1681\/ASN.2008030270","volume":"19","author":"DJ Bautz","year":"2008","unstructured":"Bautz DJ, Preston GA, Lionaki S, Hewins P, Wolberg AS, Yang JJ, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol. 2008;19(12):2421\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"1002_CR89","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.3899\/jrheum.130200","volume":"40","author":"M Hilhorst","year":"2013","unstructured":"Hilhorst M, Winckers K, Wilde B, van Oerle R, ten Cate H, Tervaert JW. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol. 2013;40(12):2042\u20136.","journal-title":"J Rheumatol"},{"issue":"8","key":"1002_CR90","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1055\/s-0039-1687911","volume":"45","author":"FA Orsi","year":"2019","unstructured":"Orsi FA, Cannegieter SC, Lijfering WM. Statin therapy to revert hypercoagulability and prevent venous thromboembolism: a narrative review. Semin Thromb Hemost. 2019;45(8):825\u201333.","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"1002_CR91","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10157-013-0854-0","volume":"17","author":"A Craven","year":"2013","unstructured":"Craven A, Robson J, Ponte C, Grayson PC, Suppiah R, Judge A, et al. ACR\/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol. 2013;17(5):619\u201321.","journal-title":"Clin Exp Nephrol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-021-01002-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T03:50:15Z","timestamp":1666756215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-021-01002-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1007\/s11926-021-01002-0","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"23 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Geetha reports personal fees (consultancy) from ChemoCentryx and Aurinia, outside the submitted work. Dr. Kronbichler reports personal fees from Novartis, from Vifor Pharma, and from TerumoBCT (speaker honorarium), outside the submitted work. Martin Windpessl, Erica L. Bettac, Philipp Gauckler, and Jae Il Shin declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"37"}}